Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer
Background: Fatal anaphylactic reactions to cetuximab remain a clinical issue, although they are associated with preexisting immunoglobulin E (IgE) directed against the galactose-α1,3-galactose epitope (α3Gal). We aimed to compare the clinical usefulness of the two assays and determine the prevalenc...
Saved in:
| Main Authors: | Y. Pointreau, C. Freneaux, T. Bejan-Angoulvant, D. Ternant, G. Calais, H. Watier |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Immuno-Oncology and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590018825000012 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review
by: Nicholas Della Marta, et al.
Published: (2025-01-01) -
IgG to Galactose-Alpha-1,3-Galactose: Impact of Alpha-Gal IgE Sensitization, Blood Type, and Tick Bites
by: Samuel M. Ailsworth, et al.
Published: (2025-05-01) -
Pre-clinical strategies and emerging technologies driving advances in the alpha-gal syndrome
by: Loren D. Erickson, et al.
Published: (2025-07-01) -
Component-Resolved and Multiplex-Specific IgE Diagnostics: Utility in Anaphylaxis and Beyond
by: Mirjana Turkalj, et al.
Published: (2025-07-01) -
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies
by: Grayson Hatfield, et al.
Published: (2023-12-01)